Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 247

Sort by

Sort Order Select

Journal Articles

T-ICAHT: Grading and Prognostic Impact of Thrombocytopenia After CAR T-cell Therapy

Blood blood.2025028833.

https://doi.org/10.1182/blood.2025028833

Published: 2025

Includes: Supplemental data

Journal Articles

Project EVOLVE: An international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia

Sara K Silbert, Alexander W Rankin, Chloe N Hoang, Alexandra Semchenkova, Regina M Myers, Elena Zerkalenkova, PhD, Hao-Wei Wang, Alexandra E Kovach, Constance M Yuan, Dana Delgado Colon, Loic Vasseur, Alex Bataller, Samuel John, Kaylyn Utley Lyons, Barbara D. Friedes, Anna Alonso-Saladrigues, Hisham Abdel-Azim, Estelle Balducci, Ahmed Aljudi, Marie Balsat, D. Nathan Biery, Aghiad Chamdin, Bill H Chang, Raymund S Cuevo, MD, Barbara De Moerloose, David S. Dickens, Ulrich A Duffner, Nicolas Duployez, Firas El Chaer, Michelle Ann Elliott, Gabriele Escherich, Sneha Fernandes, Mandi R Fitzjohn, Zhubin J Gahvari, Stephan A. Grupp, Rui Rochelle He, M.D., Cynthia Harrison, Christopher Bruce Hergott, Emily M. Hsieh, Annette S Kim, Dennis John Kuo, Daniel P Larson, Benjamin J Lee, Thibaut TL Leguay, R. Coleman Lindsley, Abhishek A. Mangaonkar, Kerstin Mezger, Holly L Pacenta, Jing Pan, Marlie R. M. Provost, Latika Puri, Sunil Sudhir Raikar, Armando Jose Martinez, Isabella Quijada Bristol, Kyle Daniel Murphy, Lauren Reiman, Michele S Redell, Kelly Reed, Gabrielle Roth Guepin, Jeremy D Rubinstein, Süreyya Savaşan, Kristian T Schafernak, Alexandra McLean Stevens, Aimee C Talleur, Naomi Torres Carapia, Jacques Vargaftig, Anant Vatsayan, Matthias Wölfl, Lipng Zhao, Susana Rives, Vanessa A. Fabrizio, Koji Sasaki, Ibrahim Aldoss, Nicolas Boissel, Susan R Rheingold, Kara L Davis, Sara Ghorashian, Elad Jacoby, Alexander Popov, Adam Joseph Lamble, Nirali N Shah

Blood blood.2024026655.

https://doi.org/10.1182/blood.2024026655

Published: 2025

Includes: Supplemental data

Journal Articles

Itacitinib for the Prevention of IEC Therapy-Associated CRS: Results From the Two-Part Phase 2 INCB 39110-211 Study

Matthew J. Frigault, Richard T. Maziarz, Jae H Park, Aleksandr Lazaryan, Nirav N Shah, Jakub Svoboda, Lazaros J. Lekakis, Ran Reshef, Christine L. Phillips, Lea Burke, Jing Lei, Michael Pratta, Rodica Morariu-Zamfir, John F. DiPersio

Blood blood.2024026586.

https://doi.org/10.1182/blood.2024026586

Published: 2025

Includes: Supplemental data

Journal Articles

Development of ALL-Hematotox: predicting post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia

Monica S. Nair, Sara K. Silbert, Kai Rejeski, Karilynn A. Wilson, Adam J. Lamble, Yannis Valtis, Bonnie Yates, Alexa Morales Arana, Roni Shouval, Kevin Curran, Rebecca A. Gardner, Haneen Shalabi, Colleen Annesley, Jae H. Park, Marion Subklewe, Nirali N. Shah

Blood (2025) 145 (11): 1136–1148.

https://doi.org/10.1182/blood.2024025910

Published: 2025

Includes: Supplemental data

Journal Articles

How I treat postimmunotherapy relapsed B-ALL

Adam J. Lamble, Alexandra E. Kovach, Nirali N. Shah

Blood (2025) 145 (1): 64–74.

https://doi.org/10.1182/blood.2024024517

Published: 2025

Journal Articles

Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Complete Remission (CR) with Undetectable Minimal Residual Disease (uMRD): Initial Report from the ECOG-ACRIN EA4151 Phase 3 Randomized Trial

Blood (2024) 144 (Supplement 2): LBA-6.

https://doi.org/10.1182/blood-2024-212973

Published: 2024

Journal Articles

Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Updated Follow-up of Transcend CLL 004

Blood (2024) 144 (Supplement 1): 4633.

https://doi.org/10.1182/blood-2024-200840

Published: 2024

Journal Articles

Rapcabtagene Autoleucel (YTB323) in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Phase II Trial Clinical Update

Blood (2024) 144 (Supplement 1): 67.

https://doi.org/10.1182/blood-2024-204264

Published: 2024

Journal Articles

A Randomized Phase II Study of Mosunetuzumab SC Plus Polatuzumab Vedotin Demonstrates Improved Outcomes Versus Rituximab Plus Polatuzumab Vedotin in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Blood (2024) 144 (Supplement 1): 989.

https://doi.org/10.1182/blood-2024-194581

Published: 2024

Journal Articles

A CD33-Deleted Allograft (Trem-cel) Enables Post-Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients with High-Risk Acute Myeloid Leukemia (AML)

John F. DiPersio, Guenther Koehne, Nirali N. Shah, Lea Bernard, Hyung C Suh, Divya Koura, Miguel Angel Perales, Roni Tamari, Muhammad Umair Mushtaq, Joseph E. Maakaron, Michael R. Loken, Darren A Stanizzi, Melissa M. Lee-Sundlov, Sanjana Thosar, Sharon L Hyzy, Glen D Raffel, Brenda W Cooper

Blood (2024) 144 (Supplement 1): 2873.

https://doi.org/10.1182/blood-2024-205641

Published: 2024

Journal Articles

Patterns of Survival in Patients with Aggressive B-Cell Lymphoma Treated with CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CART) As Second Versus Later Line of Therapy

Blood (2024) 144 (Supplement 1): 612.

https://doi.org/10.1182/blood-2024-202665

Published: 2024

Journal Articles

Outcomes of Therapies Following Discontinuation of Non-Covalent Bruton's Tyrosine Kinase Inhibitors for Patients with Chronic Lymphocytic Leukemia and Richter Transformation: Results from an International, Multicenter Study

Blood (2024) 144 (Supplement 1): 1870.

https://doi.org/10.1182/blood-2024-194748

Published: 2024

Journal Articles

Preliminary Results from a Phase 1b Study of Non-Covalent Pan-Mutant BTK Inhibitor Docirbrutinib (AS-1763) in Patients with Previously Treated B-Cell Malignancies

Nitin Jain, Catherine C. Coombs, James D'Olimpio, Nirav N. Shah, Jacqueline C. Barrientos, Seung Tae Lee, Andrew Gillis-Smith, Shuo Ma, Shirou Kirita, Masaaki Sawa, Kyoko Miyamoto, Akinori Arimura, William G. Wierda, Varsha Gandhi, Javier Pinilla-Ibarz

Blood (2024) 144 (Supplement 1): 1866.

https://doi.org/10.1182/blood-2024-208549

Published: 2024

Journal Articles

Autologous CD33CART for Children and Adolescents/Young Adults with Relapsed/Refractory AML: Phase 1/2 Clinical Trial Correlative Biology Analyses Demonstrate Potent in Vitro , In Vivo , and Ex Vivo Anti-Leukemia Activity

Tommaso Balestra, Camilo Arenas Merizalde, Robert K Chen, John Roach, Brian Bowser, Rachelle Salomon, Anthony Welch, Bonnie Yates, Kristin Schaller, Michael R Verneris, Susanne H.C. Baumeister, Emily M. Hsieh, M. Eric Kohler, Katherine Tarlock, Steven M. Devine, Richard Aplenc, Nirali N. Shah, Terry J Fry, Sarah K. Tasian

Blood (2024) 144 (Supplement 1): 369.

https://doi.org/10.1182/blood-2024-211517

Published: 2024

Journal Articles

Early Safety and Feasibility Results from a Phase II Trial of De-Escalated Ptcy and Ruxolitinib for Gvhd Prophylaxis in Older Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT

Sameem Abedin, Fateeha Furqan, Lyndsey Runaas, Walter Longo, Nirav N. Shah, Timothy S. Fenske, Marcelo C. Pasquini, William R Drobyski, Xue-Zhong Yu, Mehdi Hamadani

Blood (2024) 144 (Supplement 1): 1039.

https://doi.org/10.1182/blood-2024-200832

Published: 2024

Journal Articles

Initial Experience with CD19/CD22 BiCistronic CAR T-Cells in Children and Young Adults with Recurrent or Refractory B-Cell Malignancies

Brynn B. Duncan, Sara K. Silbert, Alexander W. Rankin, Bonnie Yates, Lauren Little, Toni Foley, Hao-Wei Wang, Constance M. Yuan, Dana I. Delgado Colon, Yanyu Wang, Jon Inglefield, John A Ligon, Hannah W. Song, Steven L. Highfill, Haneen Shalabi, David F. Stroncek, Naomi Taylor, Nirali N. Shah

Blood (2024) 144 (Supplement 1): 680.

https://doi.org/10.1182/blood-2024-198259

Published: 2024

Journal Articles

Clinical Outcomes of Transformed Follicular Lymphoma with CAR T-Cell Therapy: A US Multicenter Real-World Analysis

Blood (2024) 144 (Supplement 1): 525.

https://doi.org/10.1182/blood-2024-212106

Published: 2024

Journal Articles

Interim Results from a Phase 2 Pivotal Study (DALY II USA) of Tandem CD20-CD19-Directed Non-Cryopreserved CAR-T Cells - Zamtocabtagene Autoleucel (Zamto-Cel) in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma

Blood (2024) 144 (Supplement 1): 68.

https://doi.org/10.1182/blood-2024-208539

Published: 2024

Journal Articles

Application of Stem Cell Boost for Immune Effector Cell Associated Hematotoxicity (ICAHT) Following BCMA Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Multiple Myeloma (MM)

Blood (2024) 144 (Supplement 1): 254.

https://doi.org/10.1182/blood-2024-210725

Published: 2024

Journal Articles

Lisocabtagene Maraleucel (liso-cel) Combined with Ibrutinib (ibr) for Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Results from the Open-Label, Phase 1/2 Transcend CLL 004 Study

Blood (2024) 144 (Supplement 1): 887.

https://doi.org/10.1182/blood-2024-200339

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

T-ICAHT: Grading and Prognostic Impact of Thrombocytopenia After CAR T-cell Therapy

Project EVOLVE: An international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia

Itacitinib for the Prevention of IEC Therapy-Associated CRS: Results From the Two-Part Phase 2 INCB 39110-211 Study

Development of ALL-Hematotox: predicting post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia

How I treat postimmunotherapy relapsed B-ALL

Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Complete Remission (CR) with Undetectable Minimal Residual Disease (uMRD): Initial Report from the ECOG-ACRIN EA4151 Phase 3 Randomized Trial

Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Updated Follow-up of Transcend CLL 004

Rapcabtagene Autoleucel (YTB323) in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Phase II Trial Clinical Update

A Randomized Phase II Study of Mosunetuzumab SC Plus Polatuzumab Vedotin Demonstrates Improved Outcomes Versus Rituximab Plus Polatuzumab Vedotin in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

A CD33-Deleted Allograft (Trem-cel) Enables Post-Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients with High-Risk Acute Myeloid Leukemia (AML)

Patterns of Survival in Patients with Aggressive B-Cell Lymphoma Treated with CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CART) As Second Versus Later Line of Therapy

Outcomes of Therapies Following Discontinuation of Non-Covalent Bruton's Tyrosine Kinase Inhibitors for Patients with Chronic Lymphocytic Leukemia and Richter Transformation: Results from an International, Multicenter Study

Preliminary Results from a Phase 1b Study of Non-Covalent Pan-Mutant BTK Inhibitor Docirbrutinib (AS-1763) in Patients with Previously Treated B-Cell Malignancies

Autologous CD33CART for Children and Adolescents/Young Adults with Relapsed/Refractory AML: Phase 1/2 Clinical Trial Correlative Biology Analyses Demonstrate Potent in Vitro , In Vivo , and Ex Vivo Anti-Leukemia Activity

Early Safety and Feasibility Results from a Phase II Trial of De-Escalated Ptcy and Ruxolitinib for Gvhd Prophylaxis in Older Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT

Initial Experience with CD19/CD22 BiCistronic CAR T-Cells in Children and Young Adults with Recurrent or Refractory B-Cell Malignancies

Clinical Outcomes of Transformed Follicular Lymphoma with CAR T-Cell Therapy: A US Multicenter Real-World Analysis

Interim Results from a Phase 2 Pivotal Study (DALY II USA) of Tandem CD20-CD19-Directed Non-Cryopreserved CAR-T Cells - Zamtocabtagene Autoleucel (Zamto-Cel) in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma

Application of Stem Cell Boost for Immune Effector Cell Associated Hematotoxicity (ICAHT) Following BCMA Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Multiple Myeloma (MM)

Lisocabtagene Maraleucel (liso-cel) Combined with Ibrutinib (ibr) for Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Results from the Open-Label, Phase 1/2 Transcend CLL 004 Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only